List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
New research from Gladstone Institutes shows that chronic overactivation of dopamine-producing neurons can directly trigger their death, offering new insights into why these cells deteriorate in Parkinson’s disease which could lead to potential therapies to slow its progression.
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
Brazilian researchers have developed a new Zika virus vaccine that is safe and effective in mice – protecting against both brain inflammation and testicular damage while avoiding cross-reactions with dengue.
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
A new study shows high triglyceride levels directly cause abdominal aortic aneurysms – highlighting triglyceride-lowering therapies as a potential new treatment.
Researchers at UC San Diego have discovered a graphene-based technology that accelerates the maturation of human brain organoids, offering a safer, non-invasive way to model diseases like Alzheimer’s.
A new study has shown that small pond worms, called planaria, respond to psychiatric drugs like rodents – offering a promising new way of studying mental health conditions such as schizophrenia and addiction.
New preclinical research suggests that evenamide – a glutamate modulator – targets hippocampal hyperexcitability, potentially addressing positive, negative and cognitive symptoms of schizophrenia.
Researchers have discovered how circular extra-chromosomal DNA drives relapse in childhood cancers and found a way to target dormant “zombie” tumour cells – which could allow for the development of more durable treatments.
An interview with Thibault Géoui reveals why this technology wave might finally break through pharma's productivity crisis – and why it will take longer than the optimists claim.
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
Researchers at Florida A&M University have identified a new compound – NSL-YHJ-2-27 – that disrupts key survival pathways in aromatase inhibitor-resistant breast cancer cells – offering a potential new treatment for hard-to-treat cases.
Scientists in China have used 3D bioprinting to grow kidney tumours from patients’ own cells, creating realistic models that could speed up development of personalised treatments.
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
